IRB #

IRB00007590

Title

A Phase 1 Study of MLN8237, an Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen

Principal Investigator

Tomasz Beer

Study Purpose

The purpose of this study is to learn if the study drug (MLN8237) is effective in treating solid tumors when used in combination with a standard docetaxel regimen and to find the maxiumum tolerated dose for these drugs, when used together.

Medical Condition(s)

Multiple disease sites

Eligibility Criteria

* Subject should have a diagnosis of histologically or cytologically confirmed advanced solid tumor.
* Subject must have measureable or evaluable disease with progressing or persistent disease.

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Millennium Pharmaceuticals, Inc.

Recruitment End

Compensation Provided

No